NHS funds tech to protect prostate cancer patients during radiation treatment

An innovation that can reduce the side-effects of radiotherapy for prostate cancer patients by over 70 per cent will be rolled out across the NHS.

A deal struck by the NHS with manufacturer Boston Scientific, hospitals in England will now be encouraged to use its hydrogel device for all patients who could benefit, making radiotherapy a safer and less painful treatment option for many men.

Simon Stevens, chief executive of NHS England, said: “This further advance in NHS care for prostate cancer means patients will have safer treatment with fewer side effects. It’s another step forward in world class cancer care.”

The use of SpaceOAR hydrogel is being funded as part of a scheme to fast track specific innovations into the NHS, which over the past three years has already benefitted over 300,000 patients.

Dr Sam Roberts, director of innovation and life sciences for NHS England, said: “This programme has been amazingly successful at getting new innovations to patients, with over 300,000 patients benefitting from previous innovations, and this year we have another great selection of proven innovations.”

“We will build on this success with our commitments set out in the Long Term Plan, to support innovators and the NHS to remove barriers to uptake so patients can benefit faster.”

High-energy X-rays are targeted at the prostate, killing cancer cells and preventing them from spreading.

However, the radiation is not absorbed by the prostate, meaning that nearby healthy organs can be affected.

The hydrogel acts as a spacer, reducing the amount of radiation that can pass through the prostate and damage the rectum during treatment, by temporarily positioning it away from the high dose radiation used in treatment.

The gel, made mostly of water, is injected before treatment starts and then remains in place during radiation therapy, before being naturally absorbed by the body after about 6 months.

In studies, its use has been shown to relatively reduce life-changing side effects, such as rectal pain, bleeding and diarrhoea, by over 70%, meaning significant improvements in quality of life for those battling prostate cancer.

Heather Blake, director of support and influencing at Prostate Cancer UK, said: “While radiotherapy is very effective at treating cancer, it can also cause side effects, including bowel, urinary and sexual problems.”

“We welcome any proven innovations that will help reduce these side effects, and are pleased to see the NHS taking action to make sure they reach men as soon as possible.”